Phase I trial of APD 597 in patients with type 2 diabetes mellitus.
Latest Information Update: 05 Nov 2010
At a glance
- Drugs APD 597 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Arena Pharmaceuticals; Johnson & Johnson Innovative Medicine
Most Recent Events
- 28 Dec 2010 Status changed from recruiting to discontinued, according to an Arena Pharmaceuticals media release.
- 22 Dec 2008 New trial record.